01 — At a Glance
The Pharma CDMO Playing 4D Chess With Peptides
- 52-Week High / Low₹7,078 / ₹4,942
- Q3 FY26 Revenue₹2,604 Cr
- Q3 FY26 PAT₹583 Cr
- Q3 FY26 EPS (₹)21.96
- Annualised EPS (Q3×4)₹87.8
- Book Value₹581
- Price to Book10.9x
- Dividend Yield0.47%
- Debt / Equity0.01x
- TTM Revenue Growth14%
Auditor’s Prologue: Divi’s Labs closed Q3FY26 with ₹2,604 crore revenue (+12.3% YoY), ₹583 crore PAT, and a cool 20.4% ROCE. But here’s the kicker—the company is trading at a P/E of 66.3x, which means the market has already booked three years of future growth like it happened yesterday. One labour-code exception worth ₹74 crore crashed Q3 PAT by 9.6% YoY. Strip that out, and Q3 PAT would have been ₹657 crore. The stock is being priced like Divi’s is on the verge of becoming the next Novo Nordisk. The execution? Still in the validation phase.
02 — Introduction
The CDMO Playbook: Build Capacity, Win Customers, Hide Nothing From Regulators
Divi’s Laboratories, incorporated in 1990, manufactures Active Pharmaceutical Ingredients (APIs), custom synthesis compounds, and nutraceutical ingredients for global pharma companies. If you’ve taken an anti-inflammatory drug, a GLP-1 medication, or popped a carotenoid supplement in the last decade, there’s a non-zero chance Divi’s synthesized at least part of it in one of their seven manufacturing facilities spread across Telangana and Andhra Pradesh.
The business operates in three segments: Generic APIs (~46% of FY25 revenue), Custom Synthesis / CDMO work (~54%), and Nutraceuticals (growing fast at ₹706 crore in 9M FY26). For a company that started in the ’90s, it has aged like fine whisky—no debt, zero promotional pledges, and a ROCE that hovers between 20–35% depending on the year.
But—and this is a critical but—the stock is being priced like it’s already executed a three-year growth roadmap that’s still in pilot phase. The February 2026 earnings call revealed something juicy: Divi’s has three dedicated custom synthesis molecules queued to hit commercial volumes in Q3–Q4 of calendar year 2027. That’s 18–24 months away. The market has priced in success before the customer even files for regulatory approval. This is a masterclass in hope-inflation wrapped in a CDMO spreadsheet.
Concall Goldmine (Feb 2026): “The 3 molecules informed SEBI on the investment are the same molecules right now. Assuming approvals on time, commercial volumes somewhere in Q3, Q4 of 2027.” Translation: best case, these shipments start contributing revenue in 24 months. The market has already paid for them.
03 — Business Model: WTF Do They Even Do?
APIs, Peptides, Nutraceuticals. Pick Your Poison.
Divi’s operates three cash-generating machines, each with its own margin profile and regulatory complexity:
1. Generic APIs (~46% FY25): The company manufactures 30+ large-volume commoditized APIs (Naproxen, Gabapentin, Dextromethorphan, Levodopa, Rivaroxaban) sold to 100+ countries. These are sold at commodity pricing, face relentless cost pressure from China, and are the bread-and-butter revenue. However, backward integration projects at their Kakinada facility are attempting to reduce input costs and free up higher-value capacity at legacy sites.
2. Custom Synthesis (CDMO) (~54% FY25): Here’s where the higher margins hide. Divi’s partners with 12 of the top 20 global pharmaceutical companies to manufacture bespoke APIs and intermediates—molecules that are either too complex, too expensive, or too risky for the innovator pharmas to produce themselves. Margin profile: 34–38% EBITDA. The company’s process development and chemistry IP allow them to charge 2–4x the commodity API margin. This segment is what’s driving the P/E expansion.
3. Nutraceuticals (~7% FY25, growing): Carotenoids (Beta-Carotene, Lycopene, Astaxanthin) sold to supplement manufacturers globally. Stable, profitable, underdiscussed. ₹706 crore in 9M FY26, up from ₹576 crore in 9M FY25—a 22.6% growth story flying under radar because no one on a pharma call talks about orange pills.
Generics APIs46%Revenue Mix FY25
Custom Synthesis54%CDMO / High-Margin
NutraceuticalsGrowing₹706 Cr in 9M FY26
The Naproxen Anchovy: Divi’s is a global leader in Naproxen, an NSAID used for osteoarthritis and joint pain. It’s commodity-like, price-competitive, but also a ₹500+ crore annual revenue line that’s hard to abandon. This concentration risk is real—top 5 products = 43% of revenue in FY25, up from 41% in FY24. The company is aware but hasn’t solved it yet.
💬 If you’ve bought an OTC pain reliever from any major brand in the last 5 years, odds are Divi’s Labs made a key ingredient. Ever realize your meds are assembled by a 34-year-old Hyderabad-based CDMO? Wild, right?
04 — Financials Overview
Q3 FY26: The Numbers (With Asterisks)
Result type: Quarterly Results (Q3) | Q3 FY26 EPS: ₹21.96 | Annualised EPS (Q3×4): ₹87.8 | Note: Q3 impacted by ₹74 Cr labour code exception
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 2,604 | 2,319 | 2,715 | +12.3% | -4.1% |
| Operating Profit | 890 | 743 | 888 | +19.8% | +0.2% |
| OPM % | 34% | 32% | 33% | +200 bps | +100 bps |
| PAT (Post-Exception) | 583 | 589 | 689 | -1.0% | -15.4% |
| PAT (Pre-Exception) | 657 | 589 | 689 | +11.5% | -4.6% |
| EPS (₹) | 21.96 | 22.19 | 25.95 | -1.0% | -15.4% |
The Labour Code Bomb: India’s notified 4 labour codes (effective Nov 21, 2025) changed wage definitions, triggering an incremental employee benefit obligation of ₹74 crore recognized as an exceptional charge in Q3. This is a one-time hit, not ongoing. Strip it out: Q3 PAT would have been ₹657 crore (+11.5% YoY), and EPS would have been ₹24.74. The narrative flips from “YoY profit decline” to “double-digit growth.” Single-quarter lumpiness masked strong underlying execution. Material consumption improved to 36.3% of sales (vs 39.8% YoY)—process efficiencies and product mix working as intended.
9M FY26 Summary: Total income ₹8,081 crore (vs ₹7,041 crore YoY, +14.8%), PAT ₹1,817 crore (vs ₹1,529 crore YoY, +18.8%), with 89% of sales from exports (Europe 56.5%, North America 16.2%). Mix shift toward custom synthesis (56% vs 45% in 9M FY25) is pulling OPM up, though management cautioned against quarter-on-quarter margin interpretation due to shipment lumpiness.
05 — Valuation: Fair Value Range
Is ₹6,329 Justified, or Just Hope?
Join 10,000+ investors who read this every week.
